Skip to content

Effects of different dietary interventions on drainage tube placement time and nutritional status in chylothorax patients after Stanford type A aortic dissection

Effects of different dietary interventions on drainage tube placement time and nutritional status in chylothorax patients after Stanford type A aortic dissection: a randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113234
Enrollment
Unknown
Registered
2025-11-26
Start date
2025-01-06
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chylomax after Stanford type A aortic dissection

Interventions

fat-free diet group:Fat-free diet combined with intravenous infusion of fat emulsion
High medium chain triglycerides group:High medium chain triglycerides diet
Total parenteral nutrition group:Total parenteral nutrition

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.More than 18 years old; 2.Stanford type A aortic dissection/Intramural hematoma involving the aortic root/ascending aorta and treated with Sun's Procedure; 3.Chylothorax; 4.Subjects or their guardians (or authorized persons) fully understand the research process and agree to participate and sign a written informed consent;

Exclusion criteria

Exclusion criteria: 1.Type A aortic dissection secondary to blunt or penetrating chest trauma; 2.Mentally disturbed; 3.Pregnant or lactating women; 4.Patients undergoing treatment to reduce intracranial pressure; 5.Vital signs or hemodynamics unstable; 6.Combined with other diseases, such as severe acidosis, shock, sepsis, malignant tumor, diabetes, hyperthyroidism, refractory hypothyroidism, tuberculosis, rheumatoid arthritis, pleuritis, pneumothorax and hemothorax, parasitic diseases, nephrotic syndrome, cirrhosis, etc; 7.Hypohepatia (bilirubin 5 times higher than the upper limit of normal); 8.Renal insufficiency (glomerular filtration rate 3.0 or platelet count =5.6mmol/L), severe hypoproteinemia (albumin 1000mL/d; 17.Life expectancy <=30 days; 18.Participating in other clinical trials; 19.Unwilling to sign an informed consent form; 20.Other people deemed unsuitable for the study by the investigator;

Design outcomes

Primary

MeasureTime frame
drainage tube placement time;

Secondary

MeasureTime frame
Serum prealbumin;Serum albumin;Serum total protein;Serum retinol binding protein;Serum creatinine;Serum electrolyte;Blood coagulation;Blood routine examination;Procalcitonin;C-reactive protein;Serum amyloid A;Anthropometric measuring;Hospital stays;Hospitalization expenses;Adverse event;

Countries

China

Contacts

Public ContactLi Feng

Shandong Provincial Hospital

slyyfengli@sina.com+86 151 6886 6713

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026